- Home
- EYEN vs VGI Comparison
EYEN vs VGI Comparison
Compare EYEN & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- VGI
- Stock Information
- Founded
- EYEN 2014
- VGI 2012
- Country
- EYEN United States
- VGI United States
- Employees
- EYEN N/A
- VGI N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- VGI Investment Managers
- Sector
- EYEN Health Care
- VGI Finance
- Exchange
- EYEN Nasdaq
- VGI Nasdaq
- Market Cap
- EYEN 2.9M
- VGI N/A
- IPO Year
- EYEN 2018
- VGI N/A
- Fundamental
- Price
- EYEN N/A
- VGI $7.98
- Analyst Decision
- EYEN Hold
- VGI
- Analyst Count
- EYEN 4
- VGI 0
- Target Price
- EYEN $2.00
- VGI N/A
- AVG Volume (30 Days)
- EYEN 9.4M
- VGI 46.0K
- Earning Date
- EYEN 08-11-2025
- VGI 01-01-0001
- Dividend Yield
- EYEN N/A
- VGI 12.66%
- EPS Growth
- EYEN N/A
- VGI N/A
- EPS
- EYEN N/A
- VGI N/A
- Revenue
- EYEN $67,063.00
- VGI N/A
- Revenue This Year
- EYEN $7,680.45
- VGI N/A
- Revenue Next Year
- EYEN $315.38
- VGI N/A
- P/E Ratio
- EYEN N/A
- VGI N/A
- Revenue Growth
- EYEN 663.82
- VGI N/A
- 52 Week Low
- EYEN $0.85
- VGI $6.68
- 52 Week High
- EYEN $124.80
- VGI $7.99
- Technical
- Relative Strength Index (RSI)
- EYEN 71.65
- VGI 69.29
- Support Level
- EYEN $7.50
- VGI $7.50
- Resistance Level
- EYEN $17.18
- VGI $7.73
- Average True Range (ATR)
- EYEN 3.10
- VGI 0.07
- MACD
- EYEN 0.88
- VGI 0.02
- Stochastic Oscillator
- EYEN 81.29
- VGI 89.36
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.